Evonik Evonik

X

Find the latest Drugs in Development and Pipeline Prospector News of GemVax & KAEL.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
GemVax & KAEL
korearepublicofnew Flag
Country
Country
South Korea
Address
Address
58 Techno 11-ro, Yuseong-gu, Dajeon
Telephone
Telephone
+82 042-931-6287
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The paper is titled 'Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's already receiving donepezil and contains an analysis of the overall data from the Phase II clinical trial for Alzheimer's disease conducted in Korea.


Lead Product(s): Tertomotide

Therapeutic Area: Neurology Product Name: GV1001

Highest Development Status: Phase IIProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

GemVax's GV1001 Phase II trial evaluated the safety and efficacy of subcutaneous injection of GV1001 0.56 mg or 1.12 mg for six months in patients with moderate-to-severe Alzheimer's disease already receiving donepezil for more than three months, at 12 medical institutions.


Lead Product(s): Tertomotide

Therapeutic Area: Neurology Product Name: GV1001

Highest Development Status: Phase IIProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 23, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The pivotal decision is based on an encouraging recent analysis of results from a Phase II trial of GV1001, completed last year in Korea and if granted would apply to a second Phase IIb trial in the US now planned for early 2021.


Lead Product(s): Tertomotide

Therapeutic Area: Neurology Product Name: GV1001

Highest Development Status: Phase IIProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 06, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

GV1001 has been proven to relieve the aforementioned conditions, as well as help boost immune system, in the preclinical trial phase.


Lead Product(s): Tertomotide

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY